参考文献/References:
[1] YANNUZZI L A,SORENSON J,SPAIDE R F,LIPSON B.Idiopathic polypoidal choroidal vasculopathy (IPCV)[J].Retina,1990,10(1):1-8.
[2] IMAMURA Y,ENGELBERT M,IIDA T,FREUND K B,YANNUZZI L A.Polypoidal choroidal vasculopathy:a review[J].Surv Ophthalmol,2010,55(6):501-515.
[3] UYAMA M,WADA M,NAGAI Y,MATSUBARA T,MATSUNAGA H,FUKUSHIMA I,et al.Polypoidal choroidal vasculopathy:natural history[J].Am J Ophthalmol,2002,133(5):639-648.
[4] KIKUSHIMA W,SAKURADA Y,SUGIYAMA A,TANABE N,MATSUBARA M,MABUCHI F,et al.Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy[J].Sci Rep,2017,7(1):16461.
[5] KIKUSHIMA W,SAKURADA Y,SUGIYAMA A,TANABE N,KUME A,LIJIMA H,et al.Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy[J].Graefes Arch Clin Exp Ophthalmol,2017,255(2):311-316.
[6] MORI R,YUZAWA M,AKAZA E,HARUYAMA M.Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity[J].Jpn J Ophthalmol,2013,57(4):365-371.
[7] LALWANI G A,ROSENFELD P J,FUNG A E,DUBOVY S R,MICHELS S,FEUER W,et al.A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration:year 2 of the Pronto Study[J].Am J Ophthalmol,2009,148(1):43-58.
[8] NAKANISHI H,YAMASHIRO K,YAMADA R,GOTOH N,HAYASHI H,NAKATA I,et al.Joint effect of cigarette smoking and CFH and LOC387715/HTRA1 polymorphisms on polypoidal choroidal vasculopathy[J].Invest Ophthalmol Vis Sci,2010,51(12):6183-6187.
[9] TONG J P,CHAN W M,LIU D T,LAI T Y,CHOY K W,PANG C P,et al.Aqueoushumor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization[J].Am J Ophthalmol,2006,141(3):456-462.
[10] KOKAMO G T,YEUNG L,TERAMOTO K,LAI J C,WEE R.Polypoidal choroidal vasculopathy exudation and hemorrhage:results of monthly ranibizumab therapy at one year[J].Ophthalmologica,2014,231(2):94-102.
[11] KOKAMO G T,YEUNG L,LAI J C.Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy:6-month results[J].Br J Ophthalmol,2010,94(3):297-301.
[12] MATSUOKA M,OGATA N,OTSUJI T,NISHIMURA T,TAKAHASHI K,MATSUMURA M,et al.Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy[J].Br J Ophthalmol,2004,88(6):809-815.
[13] NG E W,ADAMIS A P.Targeting angiogenesis,the underlying disorder in neovascular age-related macular degeneration[J].Can J Ophthalmol,2005,40(3):352-368.
[14] CAMPOCHIARO P A,HAFIZ G,MIR T A,SCOTT A W,SOLOMON S,ZIMMER-GALLER I,et al.Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion:The RELATE Trial[J].Ophthalmology,2015,122(7):1426-1437.
[15] CHEUNG C M,LAI T Y,CHEN S J,CHONG V,LEE K,HTOON H,et al.Understanding indocyanine green angiography in polypoidal choroidal vasculopathy:the group experience with digital fundus photography and confocal scanning laser ophthalmoscopy[J].Retina,2014,34(12):2397-2406.
[16] CHO H J,KIM J W,LEE D W,CHO S W,KIM C G.Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy[J].Eye (Lond),2012,26(3):426-433.
[17] INOUE M,ARAKAWA A,YAMANE S,KADONOSONO K.Short-term efficacy of intravitreal aflibercept in treatment-naive patients with polypoidal choroidal vasculopathy[J].Retina,2014,34(11):2178-2184.
[18] QU J,CHENG Y,LI X,YU L,KE X.Efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy:Subgroup Analysis of the Aurora Study[J].Retina,2016,36(5):926-937.
[19] KOIZUMI H,YAMAGISHI T,YAMAZAKI T,KINOSHITA S.Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy[J].Br J Ophthalmol,2011,95(11):1555-1559.
[20] CHAN E W,ELDEEB M,LINGAM G,THOMAS D,BHARGAVA M,CHEE C K,et al.Quantitative changes in pigment epithelial detachment area and volume predict retreatment in polypoidal choroidal vasculopathy[J].Am J Ophthalmol,2017,177(2):195-205.
相似文献/References:
[1]程文武 江萍 席祖莲 张汉武 訾世莉 聂军 董彩虹.蛹虫草提取物抑制大鼠角膜新生血管的实验研究[J].眼科新进展,2012,32(5):000.
[2]于静 张明昌.苦参碱对大鼠角膜新生血管的抑制作用[J].眼科新进展,2012,32(6):000.
[3]吴正正 严京 接传红 高健生 陈皆春 宋剑涛.密蒙花方对缺氧状态下脐静脉血管内皮细胞 VEGF-VEGFR 信号转导通路的影响[J].眼科新进展,2012,32(7):000.
[4]庞霞 曲蕴慧 马跃伟 张效房 董敬民 高冬玲.去整合素金属蛋白酶9和血管内皮生长因子蛋白在眼部恶性黑色素瘤中的表达[J].眼科新进展,2012,32(7):000.
[5]刘延东.息肉状脉络膜血管病变眼底影像检查特征[J].眼科新进展,2012,32(12):000.
[6]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[7]许琴 黄亮 林素香 郑水华 肖煜晨 王雅丽.激光诱导小鼠脉络膜新生血管中膜攻击物与血管生长因子的表达[J].眼科新进展,2013,33(8):000.
[8]李小璐 马雅玲.糖尿病视网膜病变大鼠视网膜VEGF和PEDF的动态表达[J].眼科新进展,2013,33(9):000.
[9]曾莉 常以力 邵毅.血管内皮生长因子反义寡脱氧核苷酸联合血管生成素-1对糖尿病视网膜病变大鼠视网膜血管渗漏及新生血管生成的影响[J].眼科新进展,2012,32(10):000.
[10]兰兰 惠延年 曾光伟.血管生成素-1对糖尿病大鼠视网膜微血管病变、基质金属蛋白酶和血管内皮生长因子的抑制作用[J].眼科新进展,2012,32(10):000.
[11]刘子扬,夏松,杨景元,等.息肉状脉络膜血管病变抗血管内皮生长因子(VEGF)治疗后1年的视力预后与基线特征的相关性分析[J].眼科新进展,2018,38(5):440.[doi:10.13389/j.cnki.rao.2018.0102]
LIU Zi-Yang,XIA Song,YANG Jing-Yuan,et al.Correlation of 1-year vision outcomes with baseline factors in polypoidal choroidal vasculopathy patients after anti-VEGF treatment[J].Recent Advances in Ophthalmology,2018,38(10):440.[doi:10.13389/j.cnki.rao.2018.0102]
[12]刘华,许多,陈艳丽,等.康柏西普治疗息肉状脉络膜血管病变的临床疗效[J].眼科新进展,2018,38(12):1144.[doi:10.13389/j.cnki.rao.2018.0270]
LIU Hua,XU Duo,CHEN Yan-Li,et al.Clinical efficacy of conbercept in the treatment of polypoidal choroidal vasculopathy[J].Recent Advances in Ophthalmology,2018,38(10):1144.[doi:10.13389/j.cnki.rao.2018.0270]